摘要
目的探讨拉米夫定联合阿德福韦酯治疗乙肝肝硬化的疗效、安全性、耐药性。方法选择乙肝肝硬化患者78例，随机分为2组。治疗组31例，口服拉米夫定联合阿德福韦酯各1片；对照组47例，单用拉米夫定或单用阿德福韦酯治疗。均治疗24-48周。结果治疗组治疗12、24个月时病毒学应答、治疗12个月时生化学应答与对照组比较均有显著性差异（均P〈0．01），未发现严重的不良反应。结论拉米夫定联合阿德福韦酯治疗乙肝肝硬化，不易产生耐药性，并可起互补作用，患者能长期稳定病情。
Objective To investigate clinical efficacy,safety and drug resistance of Lamivudine combined with Aadefovir dipivoxil in hepatitis B liver cirrhosis. Methods Seventy-eight cases of hepatitis B were randomly divided into two groups with liver cirrhosis divided into 31 cases of treatment group. Lamivudine combined with oral Adefovir dipivoxil treatment of one of the 24- 48 weeks. And with the control group,47 cases of Lamivudine alone, compared to Adefovir dipivoxil. Treatment kept for 24-48 weeks. Results In treatment group after 12 and 24 months of treatment virological response and biochemical analysis response were significantly different from that in control group （P〈0.01）. No serious adverse reactions was found. Conclusion Lamivudine combined with Adefovir dipivoxil treatment off hepatitis B cirrhosis shows no resistance. Since the complementary roles, patients could receive a long-term drugs with stable condition.
出处
《实用临床医学（江西）》
CAS
2009年第3期18-19,22,共3页
Practical Clinical Medicine
关键词
肝硬化
乙型肝炎
拉米夫定
阿德福韦酯
耐药性
cirrhosis, hepatitis B
Lamivudine
Adefovir dipivoxil
drug resistance
